Diabetes drug Actos linked to bladder cancer

| Drug Lawsuits

This week on the Beasley Allen Report, host Gibson Vance welcomes Beasley Allen lawyer Roger Smith. Roger is an attorney in the firm’s Mass Torts section and is working on cases where people taking the Type II diabetes medication Actos have developed bladder cancer. Actos is manufactured by Takeda Pharmaceuticals.

Recently, the FDA issued a warning saying people who have been taking the drug for a year or longer have an increased risk of developing bladder cancer. Interim results from a 10-year American study found long-term Actos users had 40 percent more bladder cancers than people who never took the drug. Bladder cancer kills about 15,000 people per year in the U.S. The drug also may be linked to congestive heart failure.

In the past, Roger also worked on cases involving other diabetes drugs, Rezulin and Avandia, which were also linked to liver failure and congestive heart failure, respectively. Rezulin was taken off the market in 2000, and Avandia use was severely restricted in 2010. In addition to litigation surrounding Actos, Roger also is working on cases involving the antidepressant Zoloft, which has been linked to birth defects in babies born to mothers who took the drug during pregnancy.

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

Respectful, understanding, efficient and compassionate

Beasley Allen is one of the most professional organizations I have ever had the pleasure of working with. They are respectful, understanding, efficient, and above all compassionate. They take the best care of their clients in every way possible. They keep us informed and aware of things involved in their clients cases. Their counsel is stellar in the industry. I would highly recommend them to others in their time of need and I have done so.

—Chad H.